**TABLE S1** Baseline characteristics of ASPECT-NP participants by population

| Characteristic                  | Statistic or group | EEA population dataset \((N = 231)\) | ITT population \((N = 362)\) |
|--------------------------------|--------------------|---------------------------------------|-------------------------------|
|                                |                    | Mean (SD)                             |                               |
| Age, yrs                       |                    | 60.0 (16.4)                           | 60.5 (16.7)                   |
|                                |                    | Median (min–max)                      |                               |
|                                |                    | 62.0 (18–98)                          | 62.5 (18–98)                  |
| Age group, \(n\) \(\%\)       | <65 yrs            | 131 (56.7)                            | 202 (55.8)                    |
|                                | ≥65 yrs            | 100 (43.3)                            | 160 (44.2)                    |
|                                | <75 yrs            | 184 (79.7)                            | 279 (77.1)                    |
|                                | ≥75 yrs            | 47 (20.3)                             | 83 (22.9)                     |
| Body weight, kg                |                    | 81.2 (16.6)                           | 80.9 (17.3)                   |
|                                |                    | Median (min–max)                      |                               |
|                                |                    | 80.0 (42.0–146.0)                     | 80.0 (34.0–150.1)             |
| CrCl, mL/min\(^b\)            |                    | 108.5 (60.0)                          | 105.0 (59.3)                  |
|                                |                    | Median (min–max)                      |                               |
|                                |                    | 97.1 (16.0–427.9)                     | 95.0 (16.0–427.9)             |
| CrCl category, \(n\) \(\%\)\(^b\) | ≥150 mL/min (ARC) | 46 (19.9)                             | 67 (18.5)                     |
|                                | ≥80 to <150 mL/min (normal) | 109 (47.2)                           | 160 (44.2)                    |
|                                | >50 to <80 mL/min (mild impairment) | 46 (19.9)                            | 82 (22.7)                     |
| Characteristic         | Statistic or group | EEA population dataset (N = 231) | ITT population (N = 362) |
|-----------------------|-------------------|----------------------------------|--------------------------|
|                       |                   | Mean (SD)                        | 17.4 (5.1)               | 17.5 (5.2)<sup>d</sup> |
| APACHE II score       |                   | Median (min–max)                 | 17.0 (2.0–32.0)          | 17.0 (2.0–33.0)<sup>d</sup> |
| SOFA score            |                   | Mean (SD)                        | 6.3 (2.3)                | —                        |
|                       |                   | Median (min–max)                 | 6.0 (0.0–15.0)           | —                        |
| CPIS                  |                   | Mean (SD)                        | 9.9 (1.8)                | —                        |
|                       |                   | Median (min–max)                 | 10.0 (5.0–13.0)          | —                        |
| CPIS, n (%)           | ≤6                 | 14 (6.1)                         | 25 (6.9)                 |
|                       | 7                  | 17 (7.4)                         | 29 (8.0)                 |
|                       | 8                  | 17 (7.4)                         | 45 (12.4)                |
|                       | >8                 | 183 (79.2)                       | 263 (72.7)               |
| Sex, n (%)            | Male               | 174 (75.3)                       | 262 (72.4)               |
|                       | Female             | 57 (24.7)                        | 100 (27.6)               |
| Characteristic                          | Statistic or group | EEA population dataset (N = 231) | ITT population (N = 362) |
|----------------------------------------|-------------------|---------------------------------|--------------------------|
| Race, n (%)                            | Asian             | 18 (7.8)                        | 27 (7.5)                 |
|                                        |                   |                                 |                          |
|                                        | Black or African American | 6 (2.6)        | 10 (2.8)                 |
|                                        |                   |                                 |                          |
|                                        | White             | 194 (84.0)                      | 301 (83.1)               |
|                                        |                   |                                 |                          |
|                                        | Native Hawaiian/Pacific Islander | 1 (0.4)  | 1 (0.3)                  |
|                                        |                   |                                 |                          |
|                                        | Other/not reported | 12 (5.2)                       | 23 (6.4)                 |
| Region, n (%)                          | North America     | 8 (3.5)                         | 15 (4.1)                 |
|                                        |                   |                                 |                          |
|                                        | Latin America     | 13 (5.6)                        | 21 (5.8)                 |
|                                        |                   |                                 |                          |
|                                        | Western Europe    | 35 (15.2)                       | 53 (14.6)                |
|                                        |                   |                                 |                          |
|                                        | Eastern Europe    | 147 (63.6)                      | 231 (63.8)               |
|                                        |                   |                                 |                          |
|                                        | Asia/Pacific      | 18 (7.8)                        | 28 (7.7)                 |
|                                        |                   |                                 |                          |
|                                        | Rest of world     | 10 (4.3)                        | 14 (3.9)                 |
| Prior antibacterial therapy failure for VNP, n (%) | Yes              | 34 (14.7)                      | 53 (14.6)                |
| VABP diagnosis, n (%)                  | Yes              | 182 (78.8)                     | 263 (72.7)               |
| Characteristic                                      | Statistic or group | EEA population dataset (N = 231) | ITT population (N = 362) |
|----------------------------------------------------|--------------------|----------------------------------|--------------------------|
| Diabetes, n (%)                                    | Yes                | 51 (22.1)                        | 88 (24.3)                |
| Congestive heart failure, n (%)                    | Yes                | 37 (16.0)                        | 55 (15.2)                |
| Chronic obstructive pulmonary disease, n (%)       | Yes                | 15 (6.5)                         | 40 (11.0)                |
| Bacteremic, n (%)                                  | Yes                | 37 (16.0)                        | 25 (6.9)                 |
| Gram-negative adjunct therapy, n (%)               | Yes                | 61 (26.4)                        | 103 (28.5)               |
| Gram-positive adjunct therapy, n (%)               | Yes                | 224 (97.0)                       | 350 (96.7)               |
| PaO$_2$/FiO$_2$ >240, n (%)                        | Yes                | 56 (24.2)                        | 93 (25.7)                |
| Empyema, n (%)                                     | No                 | 231 (100.0)                      | 361 (99.7)               |
| Pleural effusion, n (%)                            | No                 | 215 (93.1)                       | 323 (89.2)               |
| Ventilation of ≥5 days, n (%)                      | Yes                | 125 (54.1)                       | 182 (50.3)               |
| Hospitalization of ≥5 days, n (%)                  | Yes                | 179 (77.5)                       | 278 (76.8)               |
| Characteristic                                      | Statistic or group | EEA population dataset (N = 231) | ITT population (N = 362) |
|----------------------------------------------------|--------------------|----------------------------------|--------------------------|
| Prior antibacterial use, n (%)                     | Yes                | 214 (92.6)                       | 318 (87.8)               |
| *Enterobacterales, n (%)*                          | Yes                | 170 (73.6)                       | 195 (73.9)*              |
| Polymicrobial LRT pathogen, n (%)                  | Yes                | 91 (39.4)                        | 100 (37.9)*              |

*APACHE*, Acute Physiology and Chronic Health Evaluation; ARCl, augmented renal clearance; CPIS, Clinical Pulmonary Infection Score; CrCl, creatinine clearance; EEA, exposure–efficacy analysis; ITT, intention-to-treat; LRT, lower respiratory tract; PaO$_2$/FiOS, ratio of partial pressure of oxygen to fractional inspired oxygen; SOFA, Sequential Organ Failure Assessment; VABP, ventilator-associated bacterial pneumonia; VNP, ventilated nosocomial pneumonia.

Calculated using central laboratory data.

*$_N$ = 359.

*$_N$ = 361.

*$_N$ = 264.
**TABLE S2** Summary of 28-day all-cause mortality and clinical cure at test of cure visit for ASPECT-NP participants by baseline creatinine clearance group.$^{a,b}$

| Renal function subgroup | 28-day all-cause mortality, n/N (%) | Clinical cure at test of cure, n/N (%) |
|-------------------------|------------------------------------|--------------------------------------|
|                         | Alive  | Death          | Cure        | Failure     |
| All                     | 195/231 (84.4) | 36/231 (15.6)  | 151/231 (65.4) | 80/231 (34.6) |
| CrCl ≥15 to <30 mL/min  | 8/11 (72.7)   | 3/11 (27.3)   | 5/11 (45.5)   | 6/11 (54.5)   |
| CrCl ≥30 to ≤50 mL/min  | 15/19 (78.9)  | 4/19 (21.1)   | 8/19 (42.1)   | 11/19 (57.9)  |
| CrCl >50 mL/min         | 172/201 (85.6) | 29/201 (14.4) | 138/201 (68.7) | 63/201 (31.3) |

$^a$CrCl, creatinine clearance.

$^b$Calculated using central laboratory data.